1.Usefulness of a Short-acting β2 Agonist in Exercise for the Patient with Cervical Epidural Abscess Accompanied by Severe COPD:A Case Report
Masashi ICHIKAWA ; Yuki UCHIYAMA ; Jun SAITO ; Norihiko KODAMA ; Kazuhisa DOMEN
The Japanese Journal of Rehabilitation Medicine 2025;():23062-
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease causing dyspnea on exertion, exercise intolerance, decline in quality of life, and physical inactivity. The patient is a 78-year-old male. He complained of quadriplegia and was diagnosed with a C7/Th1 cervical epidural abscess. After treatment with antibiotics, he was transferred to our hospital. He had tetraplegia, which corresponded to the ASIA impairment scale D, and his Functional Independence Measure (FIM) motor score was 35 points. In addition, he had severe COPD; the Medical Research Council (MRC) dyspnea scale was grade 5, and the COPD assessment test (CAT) score was 26 points. He complained of dyspnea on exertion with low intensity movements. Despite rehabilitation, improvement in ADL and physical function was poor, his FIM motor score was 43 points and the Berg balance scale (BBS) score was 21 points at the 30th day. Therefore, we started assist use of a short-acting β2 agonist (SABA) before rehabilitation on the 33rd day, and his dyspnea on exertion, physical activity, and respiratory dysfunction improved. On the 83rd day, the improvement was as follows: the MRC dyspnea scale was grade 4, the CAT score was 18 points, his 6-minute walk distance was 110 m, and his BBS score was 40 points. He was weaned from continuous oxygen therapy and discharged on day 112, at which time his FIM motor score was 69 points. We considered that the assist use of SABA before rehabilitation improved his respiratory status and physical activity without worsening his respiratory function or limb muscle weakness due to dyspnea and quadriplegia.
2.A Study on Continuous Risk Management Plan Utilization after Drug Approval:
Yuki KOBAYASHI ; Rieko SAITO ; Seiko MIYAZAKI
Japanese Journal of Drug Informatics 2024;26(1):45-50
Objective: In Japan, pharmaceutical manufacturers have been required to develop a Risk Management Plan (RMP) since April 2013. Publication of the RMP is expected to enable the wide content-sharing of post-marketing risk management and its utilization among medical professionals to further enhance and strengthen post-marketing safety measures. In this study, we examined what points should be focused on for continuous utilization of RMPs after drug approvals by investigating the numbers of safety concerns addition of antineoplastic and immunomodulating agents, and where safety concerns added after approval are listed in package inserts. Furthermore, we investigated the reasons why these safety concerns were considered as such. Methods: Antineoplastics and immunomodulating agents, which account for more than half of all drugs containing new active ingredients approved in recent years, among drugs containing new active ingredients approved from fiscal year (FY) 2013 to FY 2019 were included in the study. The safety concerns (excluding important missing information) in RMPs as of April 1, 2021 for the subject drugs were compared with those at the time of approval. Safety concerns added after approval were investigated where they were listed in package inserts as of April 1, 2021. Furthermore, risks that were added as important potential risks were investigated as to why they were considered as such. Results: There were 117 risks added after approval. Those added to the important identified risks were listed in one of the sections of the package insert, whereas 11 risks were added to the important potential risks that could not be confirmed in the package inserts. Some important potential risks added after approval are suspected to have a causal relationship with the drug, but were not listed in the package inserts. Conclusion: It is important to utilize RMPs continuously to further understand risks of taking the drug.
3.The Consideration for an Unlikely Culprit Drug (Betahistine) Inducing Toxic Epidermal Necrolysis: A Case Report
Tetsuharu IKEGAMI ; Shujiro HAYASHI ; Maki OKAMOTO ; Junko KANAI ; Yuki KANEKO ; Yuki SAITO ; Tomoko KAMINAGA ; Youichiro HAMASAKI ; Ken IGAWA
Annals of Dermatology 2023;35(Suppl1):S135-S136
4.Integration of publicly available case-based data for real-time coronavirus disease 2019 risk assessment, Japan
Kota Ninomiya ; Mariko Kanamori ; Naomi Ikeda ; Kazuaki Jindai ; Yura K Ko ; Kanako Otani ; Yuki Furuse ; Hiroki Akaba ; Reiko Miyahara ; Mayuko Saito ; Motoi Suzuki ; Hitoshi Oshitani
Western Pacific Surveillance and Response 2022;13(1):43-48
In response to the outbreak of coronavirus disease 2019 (COVID-19) in Japan, a national COVID-19 cluster taskforce (comprising governmental and nongovernmental experts) was established to support the country’s Ministry of Health, Labour and Welfare in conducting daily risk assessment. The assessment was carried out using established infectious disease surveillance systems; however, in the initial stages of the pandemic these were not sufficient for real-time risk assessment owing to limited accessibility, delay in data entry and inadequate case information. Also, local governments were publishing anonymized data on confirmed COVID-19 cases on their official websites as daily press releases. We developed a unique database for nationwide real-time risk assessment that included these case lists from local government websites and integrated all case data into a standardized format. The database was updated daily and checked systematically to ensure comprehensiveness and quality. Between 15 January 2020 and 15 June 2021, 776 459 cases were logged in the database, allowing for analysis of real-time risk from the pandemic. This semi-automated database was used in daily risk assessments, and to evaluate and update control measures to prevent community transmission of COVID-19 in Japan. The data were reported almost every week to the Japanese Government Advisory Panel on COVID-19 for public health responses.
5.High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer
Shu YAZAKI ; Yuki KOJIMA ; Hiroshi YOSHIDA ; Shigemasa TAKAMIZAWA ; Rui KITADAI ; Tadaaki NISHIKAWA ; Tatsunori SHIMOI ; Kazuki SUDO ; Ayumi SAITO ; Hitomi Sumiyoshi OKUMA ; Maki TANIOKA ; Emi NOGUCHI ; Masaya UNO ; Mitsuya ISHIKAWA ; Tomoyasu KATO ; Yasuhiro FUJIWARA ; Yuichiro OHE ; Kan YONEMORI
Journal of Gynecologic Oncology 2022;33(6):e82-
Objective:
Folate receptor α (FRα) is a membrane protein expressed in various solid tumors but has limited expression in normal cells. Therefore, FRα is an attractive target for cancer treatment. This study aimed to investigate the relationship between FRα expression and the clinicopathological characteristics and survivals of cervical cancer.
Methods:
This retrospective study included patients with cervical cancer who underwent primary surgery between 2000 and 2020 at our institution. Immunohistochemical staining of FRα was performed using an anti-folate-binding protein/FBP antibody. FRα-positive staining was defined as ≥5% of tumor staining and FRα-high as ≥50% tumor staining with ≥2+ intensity. The association between FRα expression and survival was assessed using multivariate Cox regression analysis, adjusting for established prognostic factors.
Results:
Overall, 123 patients were identified, and 140 tumor samples, including 17 paired primary and metastatic samples, were evaluated. As histological types, 67 patients had squamous cell carcinoma (SCC), and 56 patients had non-SCC. All primary tumors were FRα-positive. High FRα expression was observed in 25% of the cases and differed according to histology (SCC vs. non-SCC, 14.9% vs. 37.5%, p=0.004). FRα expression was significantly higher in metastatic tumors than in primary (170 [IQR, 140–205] vs. 125 [IQR, 110–150], p=0.0006). High FRα expression was significantly associated with worse overall survival (hazard ratio, 6.73; 95% confidence interval, 2.21–20.53; p=0.001).
Conclusion
In cervical cancer, FRα expression was elevated in metastatic tumors and high expression was associated with a worse prognosis. Our study supports the development of FRα-targeted therapy for advanced cervical cancer.
6.Efficacy of the pocket-creation method with a traction device in endoscopic submucosal dissection for residual or recurrent colorectal lesions
Daisuke IDE ; Tomohiko Richard OHYA ; Mitsuaki ISHIOKA ; Yuri ENOMOTO ; Eisuke NAKAO ; Yuki MITSUYOSHI ; Junki TOKURA ; Keigo SUZUKI ; Seiichi YAKABI ; Chihiro YASUE ; Akiko CHINO ; Masahiro IGARASHI ; Akio NAKASHIMA ; Masayuki SARUTA ; Shoichi SAITO ; Junko FUJISAKI
Clinical Endoscopy 2022;55(5):655-664
Background/Aims:
Endoscopic submucosal dissection (ESD) for residual or recurrent colorectal lesions after incomplete resection is challenging because of severe fibrosis. This study aimed to compare the efficacy of the pocket-creation method (PCM) with a traction device (TD) with that of conventional ESD for residual or recurrent colorectal lesions.
Methods:
We retrospectively studied 72 patients with residual or recurrent colorectal lesions resected using ESD. Overall, 31 and 41 lesions were resected using PCM with TD and conventional ESD methods, respectively. We compared patient background and treatment outcomes between the PCM with TD and conventional ESD groups, respectively. The primary endpoints were en bloc resection and R0 resection rates. The secondary endpoints were the dissection speed and incidence of adverse events.
Results:
En bloc resection was feasible in all cases with PCM with TD, but failed in 22% of cases of conventional ESD. The R0 resection rates for PCM with TD and conventional ESD were 97% and 66%, respectively. Dissection was significantly faster in the PCM with TD group (13.0 vs. 7.9 mm2/min). Perforation and postoperative bleeding were observed in one patient in each group.
Conclusions
PCM with TD is an effective method for treating residual or recurrent colorectal lesions after incomplete resection.
7.A Practical Grading Scale for Predicting Outcomes of Radiosurgery for Dural Arteriovenous Fistulas: JLGK 1802 Study
Hirotaka HASEGAWA ; Masahiro SHIN ; Jun KAWAGISHI ; Hidefumi JOKURA ; Toshinori HASEGAWA ; Takenori KATO ; Mariko KAWASHIMA ; Yuki SHINYA ; Hiroyuki KENAI ; Takuya KAWABE ; Manabu SATO ; Toru SERIZAWA ; Osamu NAGANO ; Kyoko AOYAGI ; Takeshi KONDOH ; Masaaki YAMAMOTO ; Shinji ONOUE ; Kiyoshi NAKAZAKI ; Yoshiyasu IWAI ; Kazuhiro YAMANAKA ; Seiko HASEGAWA ; Kosuke KASHIWABARA ; Nobuhito SAITO ;
Journal of Stroke 2022;24(2):278-287
Background:
and Purpose To assess the long-term outcomes of intracranial dural arteriovenous fistula (DAVF) treated with stereotactic radiosurgery (SRS) alone or embolization and SRS (Emb-SRS) and to develop a grading system for predicting DAVF obliteration.
Methods:
This multi-institutional retrospective study included 200 patients with DAVF treated with SRS or Emb-SRS. We investigated the long-term obliteration rate and obliteration-associated factors. We developed a new grading system to estimate the obliteration rate. Additionally, we compared the outcomes of SRS and Emb-SRS by using propensity score matching.
Results:
The 3- and 4-year obliteration rates were 66.3% and 78.8%, respectively. The post-SRS hemorrhage rate was 2%. In the matched cohort, the SRS and Emb-SRS groups did not differ in the rates of obliteration (P=0.54) or post-SRS hemorrhage (P=0.50). In multivariable analysis, DAVF location and cortical venous reflux (CVR) were independently associated with obliteration. The new grading system assigned 2, 1, and 0 points to DAVFs in the anterior skull base or middle fossa, DAVFs with CVR or DAVFs in the superior sagittal sinus or tentorium, and DAVFs without these factors, respectively. Using the total points, patients were stratified into the highest (0 points), intermediate (1 point), or lowest (≥2 points) obliteration rate groups that exhibited 4-year obliteration rates of 94.4%, 71.3%, and 60.4%, respectively (P<0.01).
Conclusions
SRS-based therapy achieved DAVF obliteration in more than three-quarters of the patients at 4 years of age. Our grading system can stratify the obliteration rate and may guide physicians in treatment selection.
8.Clinical Characteristics of Esophageal Motility Disorders in Patients With Heartburn
Satsuki TAKAHASHI ; Tomoaki MATSUMURA ; Tatsuya KANEKO ; Mamoru TOKUNAGA ; Hirotaka OURA ; Tsubasa ISHIKAWA ; Ariki NAGASHIMA ; Wataru SHIRATORI ; Naoki AKIZUE ; Yuki OHTA ; Atsuko KIKUCHI ; Mai FUJIE ; Keiko SAITO ; Kenichiro OKIMOTO ; Daisuke MARUOKA ; Tomoo NAKAGAWA ; Makoto ARAI ; Jun KATO ; Naoya KATO
Journal of Neurogastroenterology and Motility 2021;27(4):545-554
Background/Aims:
Esophageal motility disorders (EMDs) contribute to the pathophysiology of gastroesophageal reflux disease. However, the causes of EMDs and their impact on gastroesophageal reflux disease-associated symptoms remain unknown. This study aims to elucidate clinical features associated with various types of EMDs in patients with heartburn symptoms.
Methods:
Of the 511 patients who underwent high-resolution manometry, 394 who were evaluated for heartburn symptoms were examined. Patients subjected to high-resolution manometry were classified into 4 groups: outflow obstruction group, hypermotility group, hypomotility group, and normal motility group. Symptoms were evaluated using 3 questionnaires. Patient characteristics and symptoms for each EMD type were compared with those of the normal motility group.
Results:
Of the 394 patients, 193 (48.9%) were diagnosed with EMDs, including 71 with outflow obstruction, 15 with hypermotility, and 107 with hypomotility. The mean dysphagia score was significantly higher in each of the 3 EMD groups compared with those with normal motility. The mean acid reflux and dyspepsia scores were significantly lower in the outflow obstruction group (P < 0.05). The mean body mass index and median Brinkman index were significantly higher in the hypermotility group (P = 0.001 and P = 0.018, respectively), whereas the mean diarrhea and constipation scores were significantly lower in the hypomotility group (P < 0.05).
Conclusions
The results of our study indicate that different EMDs have distinct characteristics. Cigarette smoking and high body mass index were associated with esophageal hypermotility. Assessment of the dysphagia symptom scores may help identify patients with EMDs.
9.Screening for Distress and Its Impact on Palliative Care Referral at a General Medical Center: Retrospective Cohort Study
Reika IKI ; Emiko SAITO ; Nobuko WADA ; Hirohito TAKATA ; Mariko SHINOMIYA ; Masatoshi SHIMADA ; Masako TANAKA ; Chinami YOSHIZUMI ; Hiroaki SAKAI ; Yuki KATAOKA
Palliative Care Research 2021;16(1):93-98
Purpose: Distress screening is mandated by Ministry of Health, Labor and Welfare of Japan, however there is few data available on its effect in actual practice. We examined the impact of distress screening on palliative care referral at Hyogo Prefectural Amagasaki General Medical Center in Japan. Materials and Methods: We implemented distress screening on cancer patients who were given chemotherapy from February 2018. Patients were referred to the palliative care team when the physicians judged the need on the basis of the screening results or when the patients themselves wanted to receive the palliative care service. We examined the number of the patients referred to the palliative care team, then we researched the changes of the number after implementation of the screening, using the regression discontinuity analysis. Results: The distress screening didn’t increase the number of the patients who were referred to the palliative care team: the estimated difference of the number was 3.32 (95% confidence interval: −3.19〜9.82). Conclusion: We implemented distress screening at our hospital but it didn’t increase palliative care referral. Only a few studies have examined how routine screening impacts clinical outcomes. We expect our study helps to research the effectiveness of screening in each healthcare facility.
10.Clinical Characteristics of Esophageal Motility Disorders in Patients With Heartburn
Satsuki TAKAHASHI ; Tomoaki MATSUMURA ; Tatsuya KANEKO ; Mamoru TOKUNAGA ; Hirotaka OURA ; Tsubasa ISHIKAWA ; Ariki NAGASHIMA ; Wataru SHIRATORI ; Naoki AKIZUE ; Yuki OHTA ; Atsuko KIKUCHI ; Mai FUJIE ; Keiko SAITO ; Kenichiro OKIMOTO ; Daisuke MARUOKA ; Tomoo NAKAGAWA ; Makoto ARAI ; Jun KATO ; Naoya KATO
Journal of Neurogastroenterology and Motility 2021;27(4):545-554
Background/Aims:
Esophageal motility disorders (EMDs) contribute to the pathophysiology of gastroesophageal reflux disease. However, the causes of EMDs and their impact on gastroesophageal reflux disease-associated symptoms remain unknown. This study aims to elucidate clinical features associated with various types of EMDs in patients with heartburn symptoms.
Methods:
Of the 511 patients who underwent high-resolution manometry, 394 who were evaluated for heartburn symptoms were examined. Patients subjected to high-resolution manometry were classified into 4 groups: outflow obstruction group, hypermotility group, hypomotility group, and normal motility group. Symptoms were evaluated using 3 questionnaires. Patient characteristics and symptoms for each EMD type were compared with those of the normal motility group.
Results:
Of the 394 patients, 193 (48.9%) were diagnosed with EMDs, including 71 with outflow obstruction, 15 with hypermotility, and 107 with hypomotility. The mean dysphagia score was significantly higher in each of the 3 EMD groups compared with those with normal motility. The mean acid reflux and dyspepsia scores were significantly lower in the outflow obstruction group (P < 0.05). The mean body mass index and median Brinkman index were significantly higher in the hypermotility group (P = 0.001 and P = 0.018, respectively), whereas the mean diarrhea and constipation scores were significantly lower in the hypomotility group (P < 0.05).
Conclusions
The results of our study indicate that different EMDs have distinct characteristics. Cigarette smoking and high body mass index were associated with esophageal hypermotility. Assessment of the dysphagia symptom scores may help identify patients with EMDs.


Result Analysis
Print
Save
E-mail